https://www.humanexa.io/ 2026-06-16T07:09:12.054Z daily 1 https://www.humanexa.io/pricing 2026-06-16T07:09:12.054Z weekly 0.95 https://www.humanexa.io/insights 2026-06-16T07:09:12.054Z weekly 0.9 https://www.humanexa.io/signals 2026-06-16T07:09:12.054Z weekly 0.9 https://www.humanexa.io/companies 2026-06-16T07:09:12.054Z weekly 0.88 https://www.humanexa.io/regulatory 2026-06-16T07:09:12.054Z weekly 0.9 https://www.humanexa.io/strategy 2026-06-16T07:09:12.054Z weekly 0.9 https://www.humanexa.io/simulations 2026-06-16T07:09:12.054Z weekly 0.9 https://www.humanexa.io/workspace 2026-06-16T07:09:12.054Z weekly 0.9 https://www.humanexa.io/welcome 2026-06-16T07:09:12.054Z weekly 0.9 https://www.humanexa.io/newsletter 2026-06-16T07:09:12.054Z weekly 0.85 https://www.humanexa.io/privacy 2026-06-16T07:09:12.054Z yearly 0.3 https://www.humanexa.io/terms 2026-06-16T07:09:12.054Z yearly 0.3 https://www.humanexa.io/contact 2026-06-16T07:09:12.054Z monthly 0.5 https://www.humanexa.io/century-of-biology 2026-06-16T07:09:12.054Z monthly 0.7 https://www.humanexa.io/bowtiedbiomed 2026-06-16T07:09:12.054Z monthly 0.7 https://www.humanexa.io/biotechtv 2026-06-16T07:09:12.054Z monthly 0.7 https://www.humanexa.io/decoding-bio 2026-06-16T07:09:12.054Z monthly 0.7 https://www.humanexa.io/asimov-press 2026-06-16T07:09:12.054Z monthly 0.7 https://www.humanexa.io/biotech-vector 2026-06-16T07:09:12.054Z monthly 0.7 https://www.humanexa.io/assets/enhertus-potential-eu-approval-could-transform-her2-treatment-landscape 2026-06-16T06:35:04.414Z weekly 0.88 https://www.humanexa.io/assets/roches-liver-disease-panel-launch-sets-new-standard-in-hepatology-diagnostics 2026-06-16T06:35:04.285Z weekly 0.88 https://www.humanexa.io/assets/enhertus-eu-approval-could-redefine-her2-treatment-landscape 2026-06-16T06:35:04.106Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-foundayo-phase-3-success-redefines-type-2-diabetes-landscape 2026-06-16T06:35:03.995Z weekly 0.88 https://www.humanexa.io/assets/roches-ventana-pten-assay-approval-enhances-competitive-position-in-prostate-can 2026-06-16T06:34:16.871Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-in-oncology-competitive-landscape-and-strategic-implicat 2026-06-16T06:34:16.477Z weekly 0.88 https://www.humanexa.io/assets/emerging-combination-therapies-and-targeted-approaches-in-liver-cancer-treatment 2026-06-16T06:33:44.680Z weekly 0.88 https://www.humanexa.io/assets/imfinzi-and-imjudos-pfs-improvement-signals-competitive-shift-in-liver-cancer 2026-06-16T06:33:44.567Z weekly 0.88 https://www.humanexa.io/assets/mercks-keytruda-and-padcev-combination-strategic-regulatory-milestone-in-bladder 2026-06-16T06:33:15.252Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-retatrutide-phase-3-success-reinforces-competitive-position-in-obesit 2026-06-16T06:32:37.300Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-retevmo-faces-competitive-pressure-ahead-of-asco-2026-presentation 2026-06-16T06:32:29.168Z weekly 0.88 https://www.humanexa.io/assets/imfinzis-promising-trial-results-enhance-competitive-position-in-bladder-cancer 2026-06-16T06:31:59.252Z weekly 0.88 https://www.humanexa.io/assets/gilead-and-mercks-islatravirlenacapavir-phase-3-success-signals-market-disruptio 2026-06-16T06:31:56.570Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-retatrutide-emerges-as-a-game-changer-in-obesity-treatment-landscape 2026-06-16T06:31:36.639Z weekly 0.88 https://www.humanexa.io/assets/tozorakimabs-phase-iii-success-positions-astrazeneca-for-copd-leadership 2026-06-16T06:05:25.270Z weekly 0.88 https://www.humanexa.io/assets/astrazenecas-ultomiris-shows-promise-in-igan-enhancing-nephrology-position 2026-06-16T06:05:04.245Z weekly 0.88 https://www.humanexa.io/assets/emerging-opportunities-in-cytokine-modulation-and-adolescent-vaccination-strateg 2026-06-16T06:04:49.076Z weekly 0.88 https://www.humanexa.io/assets/emerging-vaccine-and-treatment-opportunities-in-influenza-and-respiratory-infect 2026-06-16T06:04:48.993Z weekly 0.88 https://www.humanexa.io/assets/pfizer-and-innovents-collaboration-enhances-oncology-pipeline-amid-competitive-p 2026-06-16T06:04:28.416Z weekly 0.88 https://www.humanexa.io/assets/pfizers-berobenatide-phase-2b-results-position-it-as-a-market-leader-in-obesity 2026-06-16T06:04:08.277Z weekly 0.88 https://www.humanexa.io/assets/roches-giredestrant-data-at-asco-2026-could-redefine-er-positive-breast-cancer-t 2026-06-16T06:04:02.685Z weekly 0.88 https://www.humanexa.io/assets/nanomaterial-based-vaccines-a-disruptive-innovation-in-rotavirus-protection 2026-06-15T11:55:53.929Z weekly 0.88 https://www.humanexa.io/assets/emerging-cd2-targeted-bispecific-antibodies-challenge-her2-t-cell-engagers 2026-06-15T11:55:44.174Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-maridebart-cafraglutides-phase-3-trial-in-osa-manageme 2026-06-15T11:55:36.013Z weekly 0.88 https://www.humanexa.io/assets/duvakitugs-phase-3-study-initiation-strategic-implications-for-ulcerative-coliti 2026-06-15T11:55:23.320Z weekly 0.88 https://www.humanexa.io/assets/lillys-zepbound-launch-strategic-positioning-in-obstructive-sleep-apnea-market 2026-06-15T11:55:20.853Z weekly 0.88 https://www.humanexa.io/assets/eli-lillys-aj1-11095-phase-1-data-enhances-competitive-position-in-myelofibrosis 2026-06-15T11:54:50.459Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-sal0140s-phase-ii-trial-in-primary-aldosteronism 2026-06-14T19:07:40.137Z weekly 0.88 https://www.humanexa.io/assets/digital-innovations-in-depression-treatment-a-potential-paradigm-shift 2026-06-14T19:05:15.555Z weekly 0.88 https://www.humanexa.io/assets/innovative-behavioral-and-digital-interventions-transforming-mental-health-care- 2026-06-14T19:05:15.181Z weekly 0.88 https://www.humanexa.io/assets/strategic-implications-of-new-melanoma-biobank-for-research-and-development 2026-06-14T19:05:10.487Z weekly 0.88 https://www.humanexa.io/assets/covac-2-vaccine-emerges-as-competitive-booster-option-in-resource-limited-settin 2026-06-14T19:03:58.293Z weekly 0.88 https://www.humanexa.io/assets/rivaroxabans-potential-shift-in-anticoagulation-strategy-for-hypertrophic-cardio 2026-06-14T19:03:21.584Z weekly 0.88 https://www.humanexa.io/assets/enhancing-catheterization-protocols-for-obese-icu-patients-through-ultrasound-gu 2026-06-14T19:03:19.479Z weekly 0.88 https://www.humanexa.io/assets/cu-20101-phase-3-trial-poses-significant-threat-to-botox-market-share 2026-06-13T08:00:56.069Z weekly 0.88 https://www.humanexa.io/assets/pfizers-hympavzi-approval-enhances-pediatric-hemophilia-treatment-landscape 2026-06-13T05:00:15.589Z weekly 0.88 https://www.humanexa.io/assets/pridopidines-phase-3-trial-a-potential-breakthrough-in-als-treatment-landscape 2026-06-12T17:24:58.519Z weekly 0.88 https://www.humanexa.io/assets/astrazenecas-imfinziimjudo-trial-results-enhance-competitive-position-in-liver-c 2026-06-12T08:01:48.885Z weekly 0.88 https://www.humanexa.io/assets/impact-of-midazolam-timing-study-on-pediatric-anesthesia-practices 2026-06-12T08:01:24.133Z weekly 0.88 https://www.humanexa.io/assets/emerging-clinical-trials-in-psychiatry-strategic-implications-for-weight-managem 2026-06-12T08:00:34.117Z weekly 0.88 https://www.humanexa.io/assets/impact-of-clinical-trials-on-incontinence-associated-dermatitis-treatment-strate 2026-06-12T08:00:21.416Z weekly 0.88 https://www.humanexa.io/assets/advancements-in-drug-delivery-for-cns-infections-strategic-implications-for-amph 2026-06-11T18:01:56.418Z weekly 0.88 https://www.humanexa.io/assets/cxds-ketogenic-diet-trial-a-potential-game-changer-in-masld-treatment 2026-06-11T12:01:31.291Z weekly 0.88 https://www.humanexa.io/assets/astrazenecas-baxfendy-approval-a-strategic-shift-in-hypertension-treatment 2026-06-11T09:12:14.605Z weekly 0.88 https://www.humanexa.io/assets/microbiome-targeted-nutrition-study-could-transform-type-2-diabetes-management 2026-06-11T08:01:01.059Z weekly 0.88 https://www.humanexa.io/assets/fda-clearance-of-bridge-device-signals-regulatory-shift-in-oud-treatment-landsca 2026-06-11T06:01:36.623Z weekly 0.88 https://www.humanexa.io/assets/regulatory-approvals-reshape-competitive-landscape-in-neurology-markets 2026-06-10T14:50:50.069Z weekly 0.88 https://www.humanexa.io/assets/comparative-effectiveness-study-on-ptsd-treatments-could-reshape-market-dynamics 2026-06-10T12:01:14.440Z weekly 0.88 https://www.humanexa.io/assets/torrent-pharmaceuticals-gains-competitive-edge-with-lurasidone-hydrochloride-app 2026-06-10T06:00:36.878Z weekly 0.88 https://www.humanexa.io/assets/baxters-phenylephrine-approval-reshapes-vasopressor-market-dynamics 2026-06-10T04:54:09.378Z weekly 0.88 https://www.humanexa.io/assets/regulatory-approvals-reshape-competitive-landscape-in-cardiovascular-market 2026-06-10T04:54:09.282Z weekly 0.88 https://www.humanexa.io/assets/impax-labs-gains-competitive-edge-with-doxycycline-hyclate-approval 2026-06-10T03:19:04.136Z weekly 0.88 https://www.humanexa.io/assets/hospiras-lidocaine-approval-enhances-competitive-position-in-pain-management 2026-06-10T02:31:56.762Z weekly 0.88 https://www.humanexa.io/assets/aurobindo-pharmas-lamotrigine-approval-signals-market-disruption-in-antiepilepti 2026-06-10T02:31:07.297Z weekly 0.88 https://www.humanexa.io/assets/micro-labs-generic-approval-disrupts-hypertension-market-dynamics 2026-06-10T02:25:08.529Z weekly 0.88 https://www.humanexa.io/assets/regulatory-milestone-for-traveres-filspari-enhances-competitive-positioning 2026-06-10T00:01:50.614Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-reshape-competitive-landscape-in-immunology-market 2026-06-09T08:01:09.528Z weekly 0.88 https://www.humanexa.io/assets/upsher-smiths-deflazacort-approval-strengthens-competitive-position-in-corticost 2026-06-08T14:33:12.305Z weekly 0.88 https://www.humanexa.io/assets/strategic-engagement-essential-for-dual-prevention-pill-market-success 2026-06-08T02:28:01.220Z weekly 0.88 https://www.humanexa.io/assets/regulatory-acceptance-of-cosopt-pf-signals-competitive-shift-in-glaucoma-market 2026-06-07T06:01:37.909Z weekly 0.88 https://www.humanexa.io/assets/emerging-anesthetic-techniques-and-opioid-sparing-strategies-in-pain-management 2026-06-06T18:54:33.969Z weekly 0.88 https://www.humanexa.io/assets/emerging-therapeutics-in-copd-tozorakimab-and-nmes-trials-signal-strategic-shift 2026-06-06T14:54:00.106Z weekly 0.88 https://www.humanexa.io/assets/tozorakimabs-phase-iii-success-positions-it-as-a-leader-in-copd-treatment 2026-06-06T14:54:00.053Z weekly 0.88 https://www.humanexa.io/assets/jiangsu-hansohs-dapagliflozin-submission-intensifies-sglt2-inhibitor-competition 2026-06-06T08:00:28.047Z weekly 0.88 https://www.humanexa.io/assets/regulatory-developments-enhance-competitive-landscape-for-tyvaso-in-pah-market 2026-06-06T08:00:21.796Z weekly 0.88 https://www.humanexa.io/assets/positive-phase-iii-results-for-efzimfotase-alfa-reshape-hypophosphatasia-landsca 2026-06-03T01:14:22.460Z weekly 0.88 https://www.humanexa.io/assets/breztris-unique-positioning-as-first-triple-therapy-in-asthma-market 2026-06-03T01:14:21.674Z weekly 0.88 https://www.humanexa.io/assets/navigating-new-fda-guidance-on-pregnancy-safety-studies-in-drug-development 2026-06-03T01:14:21.514Z weekly 0.88 https://www.humanexa.io/signals/fda-odac-recommends-truqap-for-pten-deficient-prostate-cancer 2026-06-16T06:32:32.027Z weekly 0.8 https://www.humanexa.io/signals/datroway-approved-in-us-as-first-trop2-directed-adc-for-1l-triple-negative-breas 2026-06-16T06:31:51.490Z weekly 0.8 https://www.humanexa.io/signals/pfizers-lorbrena-crown-trial-reports-longest-progression-free-survival-in-advanc 2026-06-16T06:02:51.045Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-nda-for-roches-giredestrant-in-early-stage-er-positive-breast-cancer-1 2026-06-16T06:02:19.790Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-nda-for-roches-giredestrant-in-early-stage-er-positive-breast-cancer 2026-06-16T06:02:04.190Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-priority-review-for-roches-tecentriq-in-stage-iii-colon-cancer-1 2026-06-11T12:01:11.515Z weekly 0.8 https://www.humanexa.io/signals/roche-launches-liver-disease-panel-to-enhance-chronic-liver-disease-management 2026-06-16T06:34:06.112Z weekly 0.8 https://www.humanexa.io/signals/lillys-foundayo-shows-superior-a1c-reduction-and-weight-loss-in-pivotal-diabetes 2026-06-16T06:33:56.091Z weekly 0.8 https://www.humanexa.io/signals/truqap-approved-in-us-for-pten-deficient-metastatic-prostate-cancer 2026-06-16T06:33:46.468Z weekly 0.8 https://www.humanexa.io/signals/5-year-data-shows-intismeran-autogene-keytruda-reduces-melanoma-recurrence-risk- 2026-06-16T06:33:24.794Z weekly 0.8 https://www.humanexa.io/signals/lillys-retevmo-shows-83-reduction-in-disease-recurrence-for-early-stage-ret-fusi 2026-06-16T06:33:12.517Z weekly 0.8 https://www.humanexa.io/signals/lillys-foundayo-shows-superior-results-in-phase-3-trial-for-type-2-diabetes 2026-06-16T06:33:02.524Z weekly 0.8 https://www.humanexa.io/signals/imfinzi-gains-us-approval-for-early-bladder-cancer-with-bcg-combination 2026-06-16T06:32:53.274Z weekly 0.8 https://www.humanexa.io/signals/enhertu-gains-fda-approval-for-two-new-her2-early-breast-cancer-indications 2026-06-16T06:32:44.404Z weekly 0.8 https://www.humanexa.io/signals/foundayo-shows-significant-weight-reduction-in-older-adults-with-obesity-in-new- 2026-06-16T06:32:22.100Z weekly 0.8 https://www.humanexa.io/signals/lilly-to-present-phase-3-study-of-retevmo-in-ret-fusion-positive-nsclc-at-asco-2 2026-06-16T06:32:11.973Z weekly 0.8 https://www.humanexa.io/signals/lillys-retatrutide-shows-significant-weight-loss-in-phase-3-obesity-trial 2026-06-16T06:32:01.949Z weekly 0.8 https://www.humanexa.io/signals/gilead-and-merck-report-positive-phase-3-results-for-once-weekly-hiv-treatment-i 2026-06-16T06:31:41.775Z weekly 0.8 https://www.humanexa.io/signals/imfinzi-ev-shows-significant-survival-benefits-in-muscle-invasive-bladder-cancer 2026-06-16T06:31:31.676Z weekly 0.8 https://www.humanexa.io/signals/roche-advances-obesity-portfolio-with-promising-phase-ii-data-on-enicepatide-and 2026-06-16T06:31:22.496Z weekly 0.8 https://www.humanexa.io/signals/roche-advances-obesity-portfolio-with-promising-phase-ii-data-for-enicepatide-an 2026-06-16T06:31:11.369Z weekly 0.8 https://www.humanexa.io/signals/camizestrant-recommended-for-1st-line-er-positive-breast-cancer-in-eu 2026-06-16T06:31:00.877Z weekly 0.8 https://www.humanexa.io/signals/mercks-keytruda-plus-padcev-receives-positive-eu-chmp-opinion-for-muscle-invasiv 2026-06-16T06:30:51.981Z weekly 0.8 https://www.humanexa.io/signals/mercks-sacituzumab-tirumotecan-shows-os-and-pfs-improvement-in-endometrial-cance 2026-06-16T06:30:40.934Z weekly 0.8 https://www.humanexa.io/signals/roche-and-nurix-collaborate-on-btk-degrader-bexobrutideg-for-b-cell-malignancies-1 2026-06-16T06:05:30.126Z weekly 0.8 https://www.humanexa.io/signals/roche-and-nurix-collaborate-on-btk-degrader-bexobrutideg-for-b-cell-malignancies 2026-06-16T06:05:14.101Z weekly 0.8 https://www.humanexa.io/signals/tozorakimab-shows-positive-phase-iii-results-in-copd-reducing-exacerbations 2026-06-16T06:04:57.466Z weekly 0.8 https://www.humanexa.io/signals/ultomiris-meets-primary-endpoint-in-phase-iii-trial-for-igan 2026-06-16T06:04:42.021Z weekly 0.8 https://www.humanexa.io/signals/merck-and-gilead-discontinue-phase-3-study-of-trodelvy-and-keytruda-in-nsclc 2026-06-16T06:04:26.877Z weekly 0.8 https://www.humanexa.io/signals/pfizers-25vpnc-vaccine-shows-strong-phase-2-results-advancing-to-phase-3 2026-06-16T06:04:11.835Z weekly 0.8 https://www.humanexa.io/signals/pfizer-and-innovent-collaborate-on-12-early-stage-oncology-programs 2026-06-16T06:03:56.766Z weekly 0.8 https://www.humanexa.io/signals/pfizers-berobenatide-shows-promising-phase-2b-results-for-monthly-dosing-in-obes 2026-06-16T06:03:42.162Z weekly 0.8 https://www.humanexa.io/signals/roche-to-present-promising-giredestrant-data-at-asco-2026-for-early-breast-cance-1 2026-06-16T06:03:28.576Z weekly 0.8 https://www.humanexa.io/signals/roche-to-present-promising-giredestrant-data-at-asco-2026-for-early-breast-cance 2026-06-16T06:03:06.243Z weekly 0.8 https://www.humanexa.io/signals/talzenna-plus-xtandi-shows-52-rpfs-improvement-in-metastatic-prostate-cancer 2026-06-16T06:02:35.354Z weekly 0.8 https://www.humanexa.io/signals/pfizers-braftovi-regimen-nearly-doubles-progression-free-survival-in-mcrc 2026-06-16T06:01:50.639Z weekly 0.8 https://www.humanexa.io/signals/nanomaterial-based-vaccines-show-promise-for-improved-rotavirus-protection 2026-06-15T11:55:36.199Z weekly 0.8 https://www.humanexa.io/signals/novel-cd2-targeted-bispecific-antibody-enhances-t-cell-engagers-for-solid-tumors 2026-06-15T11:55:27.900Z weekly 0.8 https://www.humanexa.io/signals/phase-iii-trial-of-tr115-vs-investigators-choice-in-relapsedrefractory-periphera 2026-06-15T11:54:45.509Z weekly 0.8 https://www.humanexa.io/signals/lillys-jaypirca-shows-45-reduction-in-disease-progression-risk-in-cllsll 2026-06-15T11:54:28.604Z weekly 0.8 https://www.humanexa.io/signals/lilly-presents-promising-phase-1-data-for-first-in-class-type-ii-jak2-inhibitor- 2026-06-14T12:00:27.358Z weekly 0.8 https://www.humanexa.io/signals/rivaroxaban-trial-for-antithrombotic-prevention-in-hypertrophic-cardiomyopathy-p 2026-06-14T06:00:18.632Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-keytruda-combinations-for-adjuvant-treatment-in-clear-cell-rcc 2026-06-13T12:00:46.215Z weekly 0.8 https://www.humanexa.io/signals/roches-ventana-pten-assay-receives-fda-approval-for-prostate-cancer-companion-di 2026-06-13T12:00:20.007Z weekly 0.8 https://www.humanexa.io/signals/phase-3-study-of-cu-20101-shows-promise-for-glabellar-lines-compared-to-botox 2026-06-13T00:00:45.698Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-priority-review-for-roches-tecentriq-in-stage-iii-colon-cancer 2026-06-11T12:00:57.741Z weekly 0.8 https://www.humanexa.io/signals/fda-clears-bridge-device-for-opioid-use-disorder-treatment-efficacy-under-evalua 2026-06-11T06:01:16.361Z weekly 0.8 https://www.humanexa.io/signals/pridopidine-phase-3-trial-initiated-for-als-efficacy-and-safety-evaluation 2026-06-10T18:00:32.582Z weekly 0.8 https://www.humanexa.io/signals/lipus-and-microbubbles-enhance-amphotericin-b-delivery-for-cryptococcal-meningit 2026-06-10T12:01:18.493Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-pfizers-hympavzi-for-expanded-hemophilia-a-and-b-indications 2026-06-10T12:00:41.077Z weekly 0.8 https://www.humanexa.io/signals/lillys-retatrutide-shows-significant-weight-loss-and-pain-reduction-in-triumph-1 2026-06-07T06:01:53.253Z weekly 0.8 https://www.humanexa.io/signals/fda-extends-decision-date-for-astrazenecas-camizestrant-in-hr-positive-breast-ca 2026-06-16T06:34:14.993Z weekly 0.8 https://www.humanexa.io/signals/non-coding-rnas-as-regulators-of-aerobic-glycolysis-in-pancreatic-ductal-adenoca 2026-06-15T18:00:37.814Z weekly 0.8 https://www.humanexa.io/signals/phase-3-trial-of-maridebart-cafraglutide-in-obstructive-sleep-apnea-patients 2026-06-15T11:55:18.163Z weekly 0.8 https://www.humanexa.io/signals/phase-3-study-of-duvakitug-for-moderately-to-severely-active-ulcerative-colitis- 2026-06-15T11:55:08.806Z weekly 0.8 https://www.humanexa.io/signals/lillys-zepbound-tirzepatide-targets-moderate-obstructive-sleep-apnea-in-national 2026-06-15T11:54:58.429Z weekly 0.8 https://www.humanexa.io/signals/gsks-as03-adjuvanted-h5n8-vaccine-shows-promising-immunogenicity-and-safety-in-p 2026-06-14T12:00:17.411Z weekly 0.8 https://www.humanexa.io/signals/new-biobank-established-for-cutaneous-melanoma-and-non-melanoma-research 2026-06-14T00:01:10.724Z weekly 0.8 https://www.humanexa.io/signals/study-on-ultrasound-guidance-for-central-catheterization-in-obese-icu-patients 2026-06-13T18:00:15.311Z weekly 0.8 https://www.humanexa.io/signals/covac-2-vaccine-shows-safety-and-immunogenicity-as-covid-19-booster-in-phase-1-t 2026-06-13T12:00:56.818Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-sal0140-shows-promise-for-primary-aldosteronism 2026-06-13T12:00:34.132Z weekly 0.8 https://www.humanexa.io/signals/trial-on-mri-guided-sbrt-for-liver-metastases-aims-to-establish-safe-dose-levels 2026-06-13T06:00:18.545Z weekly 0.8 https://www.humanexa.io/signals/mri-guided-radiotherapy-trial-for-hpv-positive-oropharyngeal-cancer-initiated 2026-06-12T18:00:57.390Z weekly 0.8 https://www.humanexa.io/signals/surufatinib-trial-initiated-for-adjuvant-therapy-in-pancreatic-neuroendocrine-tu 2026-06-12T12:01:33.824Z weekly 0.8 https://www.humanexa.io/signals/phase-iiia-trial-of-mc1r-targeted-therapy-with-nivolumab-in-advanced-melanoma 2026-06-12T06:00:42.581Z weekly 0.8 https://www.humanexa.io/signals/trial-compares-silicone-barrier-spray-to-zinc-oxide-for-incontinence-associated- 2026-06-12T00:00:49.822Z weekly 0.8 https://www.humanexa.io/signals/dapagliflozin-vs-metformin-for-antipsychotic-induced-weight-gain-in-clinical-tri 2026-06-11T18:02:04.334Z weekly 0.8 https://www.humanexa.io/signals/clinical-trial-evaluates-prs-ck-storm-for-cytokine-storm-in-respiratory-infectio 2026-06-11T18:01:55.329Z weekly 0.8 https://www.humanexa.io/signals/4cmenb-and-menacwy-crm-vaccines-co-administered-safely-in-adolescents 2026-06-11T12:01:42.641Z weekly 0.8 https://www.humanexa.io/signals/study-on-timing-of-midazolam-in-pediatric-adenotonsillectomy-to-assess-stress-an 2026-06-11T12:01:30.729Z weekly 0.8 https://www.humanexa.io/signals/trial-of-cxd-and-ketogenic-diet-for-masld-shows-structured-approach 2026-06-11T12:01:21.546Z weekly 0.8 https://www.humanexa.io/signals/trial-comparing-behavioral-activation-to-relapse-prevention-for-veterans-with-au 2026-06-11T06:01:28.210Z weekly 0.8 https://www.humanexa.io/signals/pilot-trial-of-digitally-enhanced-stepped-care-for-depression-in-primary-care-in 2026-06-11T00:02:01.609Z weekly 0.8 https://www.humanexa.io/signals/study-on-image-guided-cancer-treatments-using-spectral-angio-ct 2026-06-11T00:01:50.076Z weekly 0.8 https://www.humanexa.io/signals/ai-driven-nutrition-study-for-type-2-diabetes-shows-promise-for-glycemic-control 2026-06-10T18:00:41.446Z weekly 0.8 https://www.humanexa.io/signals/study-compares-pe-therapy-pharmacotherapy-and-combination-for-ptsd-in-veterans 2026-06-10T12:01:05.430Z weekly 0.8 https://www.humanexa.io/signals/phase-ii-trial-of-venetoclax-and-rituximab-in-older-patients-with-mantle-cell-ly 2026-06-10T12:00:52.749Z weekly 0.8 https://www.humanexa.io/signals/torrents-lurasidone-hydrochloride-anda-receives-ap-status-from-fda 2026-06-10T06:00:25.356Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-spravato-esketamine-hydrochloride 2026-06-10T06:00:15.823Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-artesunate-by-amivas 2026-06-10T00:01:51.882Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-filspari-sparsentan-by-travere 2026-06-10T00:01:41.400Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-pimozide-anda219897-by-novitium-pharma 2026-06-09T18:00:49.515Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-olmesartan-medoxomil-and-hydrochlorothiazide-anda206371 2026-06-09T18:00:39.768Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplemental-application-for-concerta-by-janssen 2026-06-09T12:00:32.833Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-lidocaine-hydrochloride-04-in-dextrose-5 2026-06-09T12:00:21.418Z weekly 0.8 https://www.humanexa.io/signals/fda-approval-status-update-for-lidocaine-hydrochloride-04-in-dextrose-5 2026-06-09T06:00:23.567Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-diltiazem-hydrochloride-anda216327 2026-06-09T00:00:14.930Z weekly 0.8 https://www.humanexa.io/signals/fda-approval-process-update-for-mycophenolate-mofetil-by-strides-pharma 2026-06-08T18:01:07.009Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-supplement-for-methylprednisolone-acetate-by-sandoz 2026-06-08T12:01:09.205Z weekly 0.8 https://www.humanexa.io/signals/sandozs-methylprednisolone-anda040194-receives-ap-status-from-fda 2026-06-08T00:00:20.306Z weekly 0.8 https://www.humanexa.io/signals/glenmark-pharmaceuticals-submits-supplemental-application-for-lamotrigine 2026-06-07T18:00:33.652Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-doxycycline-hyclate-supplement-by-impax-labs 2026-06-07T12:00:23.605Z weekly 0.8 https://www.humanexa.io/signals/south-african-hcps-support-dual-prevention-pill-but-highlight-key-challenges 2026-06-07T06:01:43.998Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-ap-status-for-mesna-anda203364-submission-by-rising 2026-06-07T06:01:36.684Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-for-vabysmo-by-genentech 2026-06-07T06:01:28.328Z weekly 0.8 https://www.humanexa.io/signals/fda-approval-status-update-for-losartan-potassium-by-micro-labs 2026-06-07T00:00:24.901Z weekly 0.8 https://www.humanexa.io/signals/alembics-duloxetine-hydrochloride-supplement-receives-ap-status-from-fda 2026-06-07T00:00:16.620Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-deflazacort-supplement-application-by-upsher-smith-labs 2026-06-06T18:00:40.324Z weekly 0.8 https://www.humanexa.io/signals/aurobindo-pharmas-lamotrigine-anda-submission-receives-ap-status 2026-06-06T18:00:31.331Z weekly 0.8 https://www.humanexa.io/signals/fda-approves-supplement-for-levetiracetam-by-chartwell-rx 2026-06-06T12:01:41.453Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-application-for-cosopt-pf-supplement-by-thea-pharma 2026-06-06T12:01:32.591Z weekly 0.8 https://www.humanexa.io/signals/fda-grants-approval-for-phenylephrine-hydrochloride-by-baxter-healthcare 2026-06-06T06:00:47.187Z weekly 0.8 https://www.humanexa.io/signals/fda-submission-update-for-ondansetron-hydrochloride-anda078127 2026-06-06T06:00:35.737Z weekly 0.8 https://www.humanexa.io/signals/fda-accepts-supplement-application-for-tyvaso-treprostinil 2026-06-06T00:00:51.990Z weekly 0.8 https://www.humanexa.io/signals/fda-submission-for-dapagliflozin-by-jiangsu-hansoh-pharma 2026-06-06T00:00:40.603Z weekly 0.8 https://www.humanexa.io/signals/comparative-study-of-spsipb-vs-thoracic-paravertebral-block-for-opioid-reduction 2026-06-02T03:09:28.046Z weekly 0.8 https://www.humanexa.io/signals/pilot-study-on-geniculate-artery-embolization-for-knee-osteoarthritis-initiated 2026-06-02T03:09:23.745Z weekly 0.8 https://www.humanexa.io/signals/imfinziimjudo-shows-significant-pfs-improvement-in-early-liver-cancer-trial 2026-06-02T03:09:20.953Z weekly 0.8 https://www.humanexa.io/signals/efzimfotase-alfa-shows-positive-phase-iii-results-in-hypophosphatasia 2026-06-02T03:09:15.835Z weekly 0.8 https://www.humanexa.io/signals/trial-on-pulmonary-artery-catheters-in-cardiac-surgery-aims-to-compare-recovery- 2026-06-02T03:01:35.313Z weekly 0.8 https://www.humanexa.io/signals/tapur-study-evaluates-targeted-therapies-in-advanced-cancer-with-genomic-variant 2026-06-02T03:01:32.508Z weekly 0.8 https://www.humanexa.io/signals/tozorakimab-achieves-primary-endpoints-in-phase-iii-trials-for-copd 2026-06-02T03:01:29.578Z weekly 0.8 https://www.humanexa.io/signals/enhertu-recommended-for-eu-approval-in-her2-metastatic-solid-tumours 2026-06-02T03:01:25.861Z weekly 0.8 https://www.humanexa.io/signals/zhuochuming-trial-evaluates-3te-vs-3prn-in-diabetic-macular-edema 2026-06-01T19:50:47.438Z weekly 0.8 https://www.humanexa.io/signals/study-on-nmes-for-functional-recovery-in-copd-and-pneumonia-patients 2026-06-01T19:50:43.736Z weekly 0.8 https://www.humanexa.io/signals/fda-issues-guidance-on-postapproval-pregnancy-safety-studies 2026-06-01T19:50:38.722Z weekly 0.8 https://www.humanexa.io/signals/astrazenecas-baxfendy-receives-us-approval-for-hypertension-as-first-in-class-tr 2026-06-01T19:50:35.739Z weekly 0.8 https://www.humanexa.io/signals/breztri-gains-us-approval-as-first-triple-therapy-for-asthma 2026-06-01T19:50:32.737Z weekly 0.8 https://www.humanexa.io/companies/astrazeneca 2026-06-16T06:32:32.027Z weekly 0.82 https://www.humanexa.io/companies/roche 2026-06-16T06:32:32.027Z weekly 0.82 https://www.humanexa.io/companies/pfizer 2026-06-16T06:32:32.027Z weekly 0.82 https://www.humanexa.io/companies/merck 2026-06-16T06:30:40.934Z weekly 0.82 https://www.humanexa.io/companies/lilly 2026-06-16T06:33:12.517Z weekly 0.82 https://www.humanexa.io/companies/gsk 2026-06-16T06:04:11.835Z weekly 0.82 https://www.humanexa.io/companies/janssenpharmaceuticals 2026-06-06T12:01:41.453Z weekly 0.82 https://www.humanexa.io/companies/stridespharma 2026-06-08T18:01:07.009Z weekly 0.82 https://www.humanexa.io/companies/sciegenpharmaceuticals 2026-06-07T00:00:24.901Z weekly 0.82 https://www.humanexa.io/companies/novartis 2026-06-16T06:33:46.468Z weekly 0.82 https://www.humanexa.io/companies/gilead 2026-06-16T06:31:41.775Z weekly 0.82 https://www.humanexa.io/companies/novitiumpharma 2026-06-09T18:00:49.515Z weekly 0.82 https://www.humanexa.io/companies/alexion 2026-06-02T03:09:15.835Z weekly 0.82 https://www.humanexa.io/companies/amgen 2026-06-15T11:55:27.900Z weekly 0.82 https://www.humanexa.io/companies/abbvie 2026-06-13T00:00:45.698Z weekly 0.82 https://www.humanexa.io/companies/bristolmyerssquibb 2026-06-15T11:55:08.806Z weekly 0.82 https://www.humanexa.io/companies/prileniatherapeutics 2026-06-10T18:00:32.582Z weekly 0.82 https://www.humanexa.io/companies/prstherapeutics 2026-06-11T18:01:55.329Z weekly 0.82 https://www.humanexa.io/companies/travere 2026-06-10T00:01:41.400Z weekly 0.82 https://www.humanexa.io/companies/unitedtherapeutics 2026-06-06T00:00:51.990Z weekly 0.82 https://www.humanexa.io/companies/bayer/janssen 2026-06-14T06:00:18.632Z weekly 0.82 https://www.humanexa.io/companies/pharmaceuticalassociates 2026-06-06T06:00:35.737Z weekly 0.82 https://www.humanexa.io/companies/théapharma 2026-06-06T12:01:32.591Z weekly 0.82 https://www.humanexa.io/companies/sandoz 2026-06-08T12:01:09.205Z weekly 0.82 https://www.humanexa.io/companies/symvivo 2026-06-13T12:00:56.818Z weekly 0.82 https://www.humanexa.io/companies/cytodyn 2026-06-11T12:01:21.546Z weekly 0.82 https://www.humanexa.io/companies/torrentpharmaceuticals 2026-06-10T06:00:25.356Z weekly 0.82 https://www.humanexa.io/companies/salubrisbiotherapeutics 2026-06-13T12:00:34.132Z weekly 0.82 https://www.humanexa.io/companies/glenmarkpharmaceuticals 2026-06-07T18:00:33.652Z weekly 0.82 https://www.humanexa.io/companies/alembicpharmaceuticals 2026-06-07T00:00:16.620Z weekly 0.82 https://www.humanexa.io/companies/jiangsuhansohpharma 2026-06-06T00:00:40.603Z weekly 0.82 https://www.humanexa.io/companies/aurobindopharma 2026-06-06T18:00:31.331Z weekly 0.82 https://www.humanexa.io/companies/astrazeneca/assets/emerging-combination-therapies-and-targeted-approaches-in-liver-cancer-treatment 2026-06-16T06:33:44.680Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/enhertus-eu-approval-could-redefine-her2-treatment-landscape 2026-06-16T06:35:04.106Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/positive-phase-iii-results-for-efzimfotase-alfa-reshape-hypophosphatasia-landsca 2026-06-03T01:14:22.460Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/emerging-therapeutics-in-copd-tozorakimab-and-nmes-trials-signal-strategic-shift 2026-06-06T14:54:00.106Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/astrazenecas-baxfendy-approval-a-strategic-shift-in-hypertension-treatment 2026-06-11T09:12:14.605Z weekly 0.84 https://www.humanexa.io/companies/astrazeneca/assets/breztris-unique-positioning-as-first-triple-therapy-in-asthma-market 2026-06-03T01:14:21.674Z weekly 0.84 https://www.humanexa.io/companies/roche/assets/regulatory-developments-in-oncology-competitive-landscape-and-strategic-implicat 2026-06-16T06:34:16.477Z weekly 0.84 https://www.humanexa.io/companies/roche/assets/regulatory-acceptance-of-cosopt-pf-signals-competitive-shift-in-glaucoma-market 2026-06-07T06:01:37.909Z weekly 0.84 https://www.humanexa.io/companies/pfizer/assets/regulatory-developments-in-oncology-competitive-landscape-and-strategic-implicat 2026-06-16T06:34:16.477Z weekly 0.84 https://www.humanexa.io/companies/pfizer/assets/eli-lillys-retatrutide-emerges-as-a-game-changer-in-obesity-treatment-landscape 2026-06-16T06:31:36.639Z weekly 0.84 https://www.humanexa.io/companies/pfizer/assets/pfizers-hympavzi-approval-enhances-pediatric-hemophilia-treatment-landscape 2026-06-13T05:00:15.589Z weekly 0.84 https://www.humanexa.io/companies/merck/assets/regulatory-developments-in-oncology-competitive-landscape-and-strategic-implicat 2026-06-16T06:34:16.477Z weekly 0.84 https://www.humanexa.io/companies/lilly/assets/eli-lillys-aj1-11095-phase-1-data-enhances-competitive-position-in-myelofibrosis 2026-06-15T11:54:50.459Z weekly 0.84 https://www.humanexa.io/companies/lilly/assets/eli-lillys-retatrutide-emerges-as-a-game-changer-in-obesity-treatment-landscape 2026-06-16T06:31:36.639Z weekly 0.84 https://www.humanexa.io/companies/lilly/assets/lillys-zepbound-launch-strategic-positioning-in-obstructive-sleep-apnea-market 2026-06-15T11:55:20.853Z weekly 0.84 https://www.humanexa.io/companies/janssenpharmaceuticals/assets/regulatory-approvals-reshape-competitive-landscape-in-neurology-markets 2026-06-10T14:50:50.069Z weekly 0.84 https://www.humanexa.io/companies/stridespharma/assets/regulatory-developments-reshape-competitive-landscape-in-immunology-market 2026-06-09T08:01:09.528Z weekly 0.84 https://www.humanexa.io/companies/sciegenpharmaceuticals/assets/baxters-phenylephrine-approval-reshapes-vasopressor-market-dynamics 2026-06-10T04:54:09.378Z weekly 0.84 https://www.humanexa.io/companies/novartis/assets/regulatory-developments-in-oncology-competitive-landscape-and-strategic-implicat 2026-06-16T06:34:16.477Z weekly 0.84 https://www.humanexa.io/companies/novitiumpharma/assets/aurobindo-pharmas-lamotrigine-approval-signals-market-disruption-in-antiepilepti 2026-06-10T02:31:07.297Z weekly 0.84 https://www.humanexa.io/companies/travere/assets/regulatory-milestone-for-traveres-filspari-enhances-competitive-positioning 2026-06-10T00:01:50.614Z weekly 0.84 https://www.humanexa.io/companies/unitedtherapeutics/assets/regulatory-developments-enhance-competitive-landscape-for-tyvaso-in-pah-market 2026-06-06T08:00:21.796Z weekly 0.84 https://www.humanexa.io/companies/torrentpharmaceuticals/assets/torrent-pharmaceuticals-gains-competitive-edge-with-lurasidone-hydrochloride-app 2026-06-10T06:00:36.878Z weekly 0.84 https://www.humanexa.io/companies/jiangsuhansohpharma/assets/jiangsu-hansohs-dapagliflozin-submission-intensifies-sglt2-inhibitor-competition 2026-06-06T08:00:28.047Z weekly 0.84 https://www.humanexa.io/newsletter/3f84cd5a-99c2-49b3-b890-09f98fbce08c 2026-06-06T06:47:03.383Z monthly 0.75